TABLE 3.
(1) Median OS in months (95% CI) per treatment strategy, and (2) 5‐year OS of stage IV CRC patients diagnosed between 2008 and 2016
| Treatment strategy | Year of diagnosis | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | ||
| Median OS in months | Total Stage IV populationA |
10·8 (10·2‐11·6) |
11·0 (10·4‐11·6) |
11·2 (10·6‐12·1) |
12·0 (11·4‐12·7) |
11·2 (10·6‐11·9) |
12·4 (11·6‐13·1) |
13·5 (12·7‐14·2) |
13·2 (12·4‐14·2) |
12·5 (11·8‐13·2) |
| No antitumor treatmentB |
1·5 (1·3‐1·7) |
1·8 (1·7‐2·0) |
1·6 (1·4‐1·8) |
1·7 (1·5‐2·0) |
1·8 (1·6‐2·0) |
1·6 (1·4‐1·9) |
1·7 (1·5‐1·9) |
1·8 (1·5‐2·1) |
1·8 (1·6‐2·1) |
|
| Any antitumor therapyC |
15·5 (14·7‐16·4) |
15·3 (14·3‐16·4) |
16·5 (15·6‐17·5) |
16·6 (15·9‐17·6) |
16·2 (15·2‐17·6) |
17·3 (16·3‐18·3) |
17·7 (16·9‐18·8) |
18·6 (17·9‐19·5) |
17·3 (16·5‐18·5) |
|
| Systemic therapy ± PTRD |
15·4 (14·7‐16·3) |
14·4 (13·5‐15·4) |
15·1 (14·1‐16·1) |
14·2 (13·4‐15·3) |
13·7 (12·8‐14·3) |
14·2 (13·6‐15·0) |
15·0 (14·4‐15·9) |
14·8 (13·7‐15·9) |
13·3 (12·7‐14·1) |
|
| Systemic therapy onlyE |
12·0 (10·9‐13·0) |
11·4 (10·7‐12·4) |
12·4 (11·3‐13·2) |
11·3 (10·7‐11·9) |
11·2 (10·4‐12·0) |
11·6 (10·8‐12·6) |
13·1 (12·1‐14·1) |
12·0 (11·1‐13·2) |
11·6 10·6‐12·6) |
|
| Systemic therapy + PTRF |
20·4 (18·9‐22·4) |
20·1 (18·5‐22·4) |
19·4 (18·2‐21·4) |
19·4 (18·4‐21·1) |
18·3 (16·8‐19·8) |
19·3 (17·9‐21·0) |
20·8 (18·6‐23·0) |
19·5 (17·6‐21·0) |
18·0 (16·2‐22·4) |
|
| Metastasectomy/HIPEC + systemic therapyG |
52·4 (43·8‐58·8) |
42·3 (38·2‐55·3) |
47·4 (42·1‐54·1) |
51·5 (45·9‐56·7) |
49·5 (41·3‐58·6) |
48·0 (43·1‐54·1) |
45·1 (39·2‐52·7) |
a | a | |
| Metastasectomy/HIPEC onlyH |
28·0 (19·6‐40·6) |
42·1 (29·8‐60·8) |
38·5 (29·7‐64·4) |
44·6 (32·5‐59·0) |
35·7 (26·6‐48·0) |
37·8 (33·0‐53·9) |
41·3 (32·6‐54·9) |
a | a | |
| Percentage 5‐year OS |
Total Stage IV population |
9·1 (8·1–10·2) |
9·1 (8·1‐10·2) |
9·8 (8·8‐10·9) |
10·8 (9·8‐12·0) |
10·2 (9·2‐11·4) |
10·3 (9·3‐11·4) |
12·4 (11·2‐13·7) |
a | a |
Note: A, B, C, D, E, F, G, and H correspond to the graphs in Figure 2.
Abbreviations: HIPEC, hyperthermic intraperitoneal chemotherapy; OS, overall survival; PTR, primary tumor resection.
Results not yet available because of limited follow‐up time.